Focalin XR vs Concerta

MEDICATION COMPARISON · FROM FDA LABELS AND HEAD-TO-HEAD STUDIES

Reviewed by Tariq Halim, MD · Last medical review: October 29, 2026 · Editorial policy

Focalin XR and Concerta are both FDA-approved ADHD medicines. Focalin XR contains dexmethylphenidate hydrochloride and Concerta contains methylphenidate hydrochloride. At least one head-to-head study compares them (summarized below). Facts below come from each product’s FDA label.

Side-by-side facts (from each FDA label)

Each cell is copied from that product’s key facts, which cite its current FDA prescribing information. Durations and doses come from each product’s own label studies; they are not a head-to-head comparison.

Focalin XRConcerta
Drug classCNS Stimulant · MethylphenidatesCNS Stimulant · Methylphenidates
Active ingredientdexmethylphenidate hydrochloridemethylphenidate hydrochloride
FDA-approved ages6 years and older, including adults (not recommended under 6)6 to 65 years (FDA label)
Form and strengthsExtended-release capsule (bimodal bead); 5, 10, 15, 20, 25, 30, 35, 40 mg capsulesExtended-release tablet (OROS); 18 mg, 27 mg, 36 mg, 54 mg tablets (72 mg doses use a combination of tablets)
Usual dose and maximum (label)Start 5 mg (children) or 10 mg (adults) once daily; maximum 30 mg/day (children) or 40 mg/day (adults).New to methylphenidate: start 18 mg once daily (adults 18 or 36 mg); maximum 54 mg/day (ages 6–12) or 72 mg/day (13–65).
Duration (label)Benefit at every time point measured through 12 hours in children’s classroom studies.About 10–12 hours after a morning dose; benefit lasted through 12 hours in the label’s studies in children.
DEA scheduleSchedule II controlled substance (CII)Schedule II controlled substance (CII)
GenericGeneric available (see Generic manufacturers)Generic available (see Generic manufacturers)
Label datePrescribing Information revised 09/2025 (DailyMed)Prescribing Information revised 04/2026 (DailyMed)
Availability (site status, Oct 2026)Partial shortage (ASHP)ER tablet shortage · brand available

Main differences in plain words

  • Focalin XR contains dexmethylphenidate hydrochloride; Concerta contains methylphenidate hydrochloride.
  • Form: Focalin XR: extended-release capsule (bimodal bead); Concerta: extended-release tablet (OROS).
  • Controlled status: both: Schedule II controlled substance (CII).
  • Generic: Focalin XR: Generic available; Concerta: Generic available.

What studies compare them

The studies below include at least one direct (head-to-head) comparison of Focalin XR and Concerta or their active formulations. Only head-to-head trials, analyses of them and network meta-analyses are used for comparisons on this page; read the note under each study for what it can and cannot show.

  • Randomized controlled trial

    Focalin XR vs Concerta-type methylphenidate ER, children 6–12

    In a laboratory classroom crossover study in 84 children, Focalin XR acted faster and more strongly in the morning than extended-release racemic methylphenidate (the OROS type), while the racemic product had a greater effect at the end of the 12-hour day. Both beat placebo at most time points.

    Direct comparison of Focalin XR with extended-release racemic methylphenidate of the OROS (Concerta) type.

    Multicenter, double-blind crossover, n=84, ages 6–12, stabilized on d,l-MPH 40–60 mg or d-MPH 20–30 mg/day: d-MPH-ER 20 and 30 mg vs d,l-MPH-ER 36 and 54 mg vs placebo. Primary: SKAMP-Combined change at 2 h, d-MPH-ER 20 mg greater than d,l-MPH-ER 36 mg (p<0.001). d-MPH-ER: more rapid onset and greater morning effect; d,l-MPH-ER: greater effect at the end of the 12-hour day. All active treatments beat placebo at most time points to 12 h.

    Funding / affiliation: First author affiliated with Novartis (Focalin XR manufacturer) per PubMed record.

    Muniz R, Brams M, Mao A, et al. (2008). Efficacy and safety of extended-release dexmethylphenidate compared with d,l-methylphenidate and placebo in the treatment of children with attention-deficit/hyperactivity disorder: a 12-hour laboratory classroom study. J Child Adolesc Psychopharmacol 18(3):248-56. DOI · PubMed 18582179

Switching between them (label)

What each FDA label says about starting it after another medicine. Switch the clinician view on to see the full label wording and any dose tables. More in the switching guide.

Focalin XR (label section 2.2, Prescribing Information, revised 09/2025): Focalin XR contains dexmethylphenidate, the more active of the two mirror-image forms that make up methylphenidate (label 12.2), and the label starts it at half your current daily methylphenidate dose.

For patients currently taking racemic methylphenidate, start Focalin XR at half (1/2) the total daily methylphenidate dose.

Focalin XR (label section 2.2, Prescribing Information, revised 09/2025): From Focalin tablets, the label allows the same total daily dose as Focalin XR.

Patients taking Focalin (dexmethylphenidate) immediate-release tablets may be given the same total daily dose of Focalin XR.

Concerta (label section 2.4, Prescribing Information, revised 04/2026): If you take short-acting methylphenidate two or three times a day, the Concerta label gives a matching once-a-morning starting dose.

Starting dose for patients switching from immediate-release methylphenidate given two or three times daily (10–60 mg/day). The 72 mg dose is only for patients 13–65 years old. Adjust in 18 mg steps at weekly intervals.

Previous immediate-release methylphenidateConcerta starting dose
5 mg two or three times daily18 mg every morning
10 mg two or three times daily36 mg every morning
15 mg two or three times daily54 mg every morning
20 mg two or three times daily72 mg every morning (ages 13–65 only)

For clinicians

Label facts are from each product’s current prescribing information (Focalin XR: revised 09/2025; Concerta: revised 04/2026). Evidence summaries show the study detail and funding; comparative statements are limited to head-to-head trials, analyses of them and network meta-analyses. Indirect comparisons (for example, matching-adjusted indirect comparisons) are not used for efficacy claims.

Talk to your prescriber. These two medicines are not interchangeable at the same dose unless a label says so. Bring this page to your appointment if it helps, but do not change, stop or swap medicines on your own.

Frequently asked questions

What is the difference between Focalin XR and Concerta?

Focalin XR contains dexmethylphenidate hydrochloride (extended-release capsule (bimodal bead)); Concerta contains methylphenidate hydrochloride (extended-release tablet (OROS)). Focalin XR: Schedule II controlled substance (CII). Concerta: Schedule II controlled substance (CII). The side-by-side table on this page lists approved ages, doses, duration and generic status from each label.

Is Focalin XR more effective than Concerta?

Muniz 2008: In a laboratory classroom crossover study in 84 children, Focalin XR acted faster and more strongly in the morning than extended-release racemic methylphenidate (the OROS type), while the racemic product had a greater effect at the end of the 12-hour day. Both beat placebo at most time points. Results from one study population may not apply to every patient; the best choice depends on the person.

Which lasts longer, Focalin XR or Concerta?

Per the labels: Focalin XR: Benefit at every time point measured through 12 hours in children’s classroom studies. Concerta: About 10–12 hours after a morning dose; benefit lasted through 12 hours in the label’s studies in children. These figures come from separate label studies, not from one study comparing the two. In a head-to-head study (Muniz 2008): In a laboratory classroom crossover study in 84 children, Focalin XR acted faster and more strongly in the morning than extended-release racemic methylphenidate (the OROS type), while the racemic product had a greater effect at the end of the 12-hour day. Both beat placebo at most time points.

Can you switch from Focalin XR to Concerta?

Neither label gives a milligram conversion between these two products. Focalin XR label: For patients currently taking racemic methylphenidate, start Focalin XR at half (1/2) the total daily methylphenidate dose. Patients taking Focalin (dexmethylphenidate) immediate-release tablets may be given the same total daily dose of Focalin XR. Concerta label: Starting dose for patients switching from immediate-release methylphenidate given two or three times daily (10–60 mg/day). The 72 mg dose is only for patients 13–65 years old. Adjust in 18 mg steps at weekly intervals. Any switch is planned and adjusted by the prescriber.

Are Focalin XR and Concerta available as generics?

Focalin XR: Generic available. Concerta: Generic available. Current supply is tracked on the availability tracker page.

Sources

  • Sandoz Inc. Focalin XR (dexmethylphenidate hydrochloride) extended-release capsules, CII. Prescribing Information, revised 09/2025. DailyMed (accessed Oct 2026).
  • Janssen Pharmaceuticals, Inc. Concerta (methylphenidate HCl) Extended-Release Tablets Prescribing Information, revised 04/2026. DailyMed (accessed Oct 2026).
  • Muniz R, Brams M, Mao A, et al. Efficacy and safety of extended-release dexmethylphenidate compared with d,l-methylphenidate and placebo in the treatment of children with attention-deficit/hyperactivity disorder: a 12-hour laboratory classroom study. J Child Adolesc Psychopharmacol. 2008;18(3):248-56. PubMed
EDUCATIONAL INFORMATION ONLY. Not medical advice. Medication decisions require individualized assessment by a qualified clinician. Do not start, stop, switch or change the dose of a medication without your prescriber. See the medical disclaimer.
Back to top